



Press Release June 30, 2016

Genovis and Promega sign global license agreement and settle litigation

Genovis has reached a settlement in its patent infringement lawsuit with Promega Corp. and agreed to a royalty bearing, worldwide license to the patents-in-suit.

The settlement ends all ongoing patent-infringement claims between the parties and Promega has agreed to a royalty bearing, worldwide license to the patents-in-suit, thereby ending the lawsuit between the parties. The specific terms of the contract are confidential.

“I am pleased we were able to reach a settlement with a favorable business solution that accommodates Genovis’ long term growth strategy,” says Fredrik Olsson, CEO of Genovis.

For additional information, please contact:

Fredrik Olsson, CEO, Genovis AB

T: +46 (0)46-12 12 33

E: fredrik.olsson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA).

Genovis shares are listed on NASDAQ First North Stockholm and Consensus is our certified advisor, t: +46(0) 31 745 50 00